Allergic contact dermatitis is an important cause of periorbital dermatitis. Topical ophthalmic agents are relevant sensitizers. Contact dermatitis to ophthalmic medications can be challenging to diagnose and manage given the numerous possible offending agents, including both active and inactive ingredients. Furthermore, a substantial body of literature reports false-negative patch test results to ophthalmic agents. Subsequently, numerous alternative testing methods have been described. This review outlines the periorbital manifestations, causative agents, and alternative testing methods of allergic contact dermatitis to ophthalmic medications.
Get full access to this article
View all access options for this article.
References
1.
GuinJD. Eyelid dermatitis: a report of 215 patients. Contact Dermatitis, 2004; 50(2):87–90.
2.
GuinJD. Eyelid dermatitis: experience in 203 cases. J Am Acad Dermatol, 2002; 47(5):755–765.
3.
ValsecchiR, ImbertiG, MartinoD, et al.Eyelid dermatitis: an evaluation of 150 patients. Contact Dermatitis, 1992; 27(3):143–147.
4.
HerbstRA, UterW, PirkerC, et al.Allergic and non-allergic periorbital dermatitis: patch test results of the Information Network of the Departments of Dermatology during a 5-year period. Contact Dermatitis, 2004; 51(1):13–19.
5.
LandeckL, JohnSM, GeierJ. Topical ophthalmic agents as allergens in periorbital dermatitis. Br J Ophthalmol, 2014; 98:259–262.
6.
LandeckL, JohnSM, GeierJ. Periorbital dermatitis in 4779 patients—patch test results during a 10-year period. Contact Dermatitis, 2014; 70(4):205–212.
7.
ZugKA, PalayDA, RockB. Dermatologic diagnosis and treatment of itchy red eyelids. Surv Ophthalmol, 1996; 40(4):293–306.
8.
MorrisS, BarlowR, SelvaD, et al.Allergic contact dermatitis: a case series and review for the ophthalmologist. Br J Ophthalmol, 2011; 95(7):903–908.
9.
OkerekeUR, CohenDE. The utility of chamber scarification in the detection of allergic contact dermatitis to ophthalmic solutions. Dermatitis, 2014; 25(6):373–374.
10.
KudoH, TanakaT, MiyachiY, et al.Contact dermatitis from sodium cromoglycate eyedrops. Contact Dermatitis, 1988; 19(4):312.
11.
YamamotoY, WadaM, NakaiN, et al.Allergic contact dermatitis due to epsilon-aminocaproic acid: a case report and mini-review of the published work. J Dermatol, 2013; 40(4):301–303.
LandeckL, SchalockPC, BadenLA, et al.Periorbital contact sensitization. Am J Ophthalmol, 2010; 150(3):366–370e2.
16.
HoldinessMR. Contact dermatitis to topical drugs for glaucoma. Am J Contact Dermat, 2001; 12(4):217–219.
17.
de GrootAC, van GinkelCJ, BruynzeelDP, et al.Contact allergy to eyedrops containing beta-blockers. Ned Tijdschr Geneeskd, 1998; 142(18):1034–1036.
18.
JappeU, UterW, Menezes de PáduaCA, et al.Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993–2004. Acta Derm Venereol, 2006; 86(6):509–514.
19.
CarrièreM, Giordano-LabadieF, SchwarzeHP, et al.Difficulties in the interpretation of patch test reactions to ophthalmic beta-blockers. Contact Dermatitis, 1998; 39(6):319–320.
20.
Gonzalo-GarijoMA, ZamboninoMA, Pérez-CalderónR, et al.Allergic contact dermatitis due to carteolol, with good tolerance to betaxolol. Dermatitis, 2011; 22(4):232–233.
21.
ZucchelliV, SilvaniS, VezzaniC, et al.Contact dermatitis from levobunolol and befunolol. Contact Dermatitis, 1995; 33(1):66–67.
22.
O’DonnellBF, FouldsIS. Contact allergy to beta-blocking agents in ophthalmic preparations. Contact Dermatitis, 1993; 28(2):121–122.
23.
NinoM, SuppaF, AyalaF, et al.Allergic contact dermatitis due to the beta-blocker befunolol in eyedrops, with cross-sensitivity to carteolol. Contact Dermatitis, 2001; 44(6):369.
24.
QuiralteJ, FloridoF, de San PedroBS. Allergic contact dermatitis from carteolol and timolol in eyedrops. Contact Dermatitis, 2000; 42(4):245.
25.
CorazzaM, VirgiliA, MantovaniL, et al.Allergic contact dermatitis from cross-reacting beta-blocking agents. Contact Dermatitis, 1993; 28(3):188–189.
26.
JerstadKM, WarshawE. Allergic contact dermatitis to latanoprost. Am J Contact Dermat, 2002; 13(1):39–41.
27.
Pérez-RodríguezE, González-PérezR, PozaP, et al.Contact dermatitis caused by latanoprost-containing eye drops with good tolerance to bimatoprost eye drops. Contact Dermatitis, 2008; 58(6):370–371.
ParraA, CasasL, TomboMJ, et al.Contact dermatitis from dipivefrine with possible cross-reaction to epinephrine. Contact Dermatitis, 1998; 39(6):325–326.
42.
GaspariAA. Contact allergy to ophthalmic dipivalyl epinephrine hydrochloride: demonstration by patch testing. Contact Dermatitis, 1993; 28(1):35–37.
43.
SodhiPK, VermaL, RatanJ. Dermatological side effects of brimonidine: a report of three cases. J Dermatol, 2003; 30(9):697–700.
44.
ManniG, CentofantiM, SacchettiM, et al.Demographic and clinical factors associated with development of brimonidine tartrate 0.2%–induced ocular allergy. J Glaucoma, 2004; 13(2):163–167.
45.
SwansonLA, WarshawEM. Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea. J Am Acad Dermatol, 2014; 71(4):832–833.
46.
SilvestreJF, CarneroL, RamónR, et al.Allergic contact dermatitis from apraclonidine in eyedrops. Contact Dermatitis, 2001; 45(4):251.
47.
CusanoF, LucianoS, CapozziM, et al.Contact dermatitis from pilocarpine. Contact Dermatitis, 1993; 29(2):99.
48.
O’DonnellBF, FouldsIS. Contact allergic dermatitis and contact urticaria due to topical ophthalmic preparations. Br J Ophthalmol, 1993; 77(11):740–741.
49.
OrtizFJ, PostigoC, IvarsJ, et al.Allergic contact dermatitis from pilocarpine and thimerosal. Contact Dermatitis, 1991; 25(3):203–204.
50.
DecraeneT, GoossensA. Contact allergy to atropine and other mydriatic agents in eye drops. Contact Dermatitis, 2001; 45(5):309–310.
51.
de MisaRF, SuárezJ, FelicianoL, et al.Allergic periorbital contact dermatitis due to atropine. Clin Exp Dermatol, 2003; 28(1):97–98.
ParenteG, PazzagliaM, VincenziC, et al.Contact dermatitis from pheniramine maleate in eyedrops. Contact Dermatitis, 1999; 40(6):338.
55.
SuchiST, GuptaA, SrinivasanR. Contact allergic dermatitis and periorbital depigmentation after using olapatidine eye drops. Indian J Ophthalmol, 2008; 56(5):439–440.
56.
NiizekiH, InamotoN, NakamuraK, et al.Contact dermatitis from ketotifen fumarate eyedrops. Contact Dermatitis, 1994; 31(4):266.
57.
CamarasaJG, Serra-BaldrichE, MonrealP, et al.Contact dermatitis from sodium-cromoglycate–containing eyedrops. Contact Dermatitis, 1997; 36(3):160–161.
MiyazatoH, YamaguchiS, TairaK, et al.Allergic contact dermatitis due to diclofenac sodium in eye drops. J Dermatol, 2011; 38(3):276–279.
60.
ValsecchiR, PanseraB, LeghissaP, et al.Allergic contact dermatitis of the eyelids and conjunctivitis from diclofenac. Contact Dermatitis, 1996; 34(2):150–151.
61.
UedaK, HigashiN, KumeA, et al.Allergic contact dermatitis due to diclofenac and indomethacin. Contact Dermatitis, 1998; 39(6):323.
62.
DevleeschouwerV, RoelandtsR, GarmynM, et al.Allergic and photoallergic contact dermatitis from ketoprofen: results of (photo) patch testing and follow-up of 42 patients. Contact Dermatitis, 2008; 58(3):159–166.
63.
Sánchez-PérezJ, LópezMP, De Vega HaroJM, et al.Allergic contact dermatitis from gentamicin in eyedrops, with cross-reactivity to kanamycin but not neomycin. Contact Dermatitis, 2001; 44(1):54.
64.
MarianiR, TardioM, BassiR, et al.Allergic contact conjunctivitis without eyelid involvement. Contact Dermatitis, 1991; 24(3):227.
KimuraM, KawadaA. Contact sensitivity induced by neomycin with cross-sensitivity to other aminoglycoside antibiotics. Contact Dermatitis, 1998; 39(3):148–150.
67.
CaraffiniS, AssalveD, StingeniL, et al.Allergic contact conjunctivitis and blepharitis from tobramycin. Contact Dermatitis, 1995; 32(3):186–187.
68.
HagenSL, GreyKR, WarshawEM. Tobramycin sensitivity is not consistently detected by neomycin. Dermatitis, 2016; 27(3):152–155.
69.
Flavia Monteagudo PazA, Francisco Silvestre SalvadorJ, Latorre MartínezN, et al.Allergic contact dermatitis caused by azithromycin in an eye drop. Contact Dermatitis, 2011; 64(5):300–301.
70.
Le CozCJ, SantinelliF. Facial contact dermatitis from chloramphenicol with cross-sensitivity to thiamphenicol. Contact Dermatitis, 1998; 38(2):108–109.
NaitoT, ShiotaH, MimuraY. Side effects in the treatment of herpetic keratitis. Curr Eye Res, 1987; 6(1):237–239.
73.
Millán-ParrillaF, de la CuadraJ. Allergic contact dermatitis from trifluoridine in eyedrops. Contact Dermatitis, 1990; 22(5):289.
74.
van KetelWG. Allergy to idoxuridine eyedrops. Contact Dermatitis, 1977; 3(2):106–107.
75.
CirkelPK, van KetelWG. Allergic contact dermatitis to trifluorothymidine eyedrops. Contact Dermatitis, 1981; 7(1):49–50.
76.
FalcoLA, GruossoPJ, SkolnickK, et al.Topical interferon alpha 2 beta therapy in the management of conjunctival papilloma. Optometry, 2007; 78(4):162–166.
77.
PigattoPD, BigardiA, LegoriA, et al.Allergic contact dermatitis from beta-interferon in eyedrops. Contact Dermatitis, 1991; 25(3):199–200.
78.
WictorinA, HanssonC. Allergic contact dermatitis from a bismuth compound in an eye ointment. Contact Dermatitis, 2001; 45(5):318.
79.
CumurcuT, SenerS, CavdarM. Periorbital allergic contact dermatitis following topical mitomycin C eye drop application. Cutan Ocul Toxicol, 2011; 30(3):239–240.
80.
DaniellM, MainiR, ToleD. Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Experiment Ophthalmol, 2002; 30(2):94–98.
81.
InuiS, OzawaK, SongM, et al.Contact dermatitis due to pirfenoxone. Contact Dermatitis, 2004; 50(6):375–376.
DannakerCJ, MaibachHI, AustinE. Allergic contact dermatitis to proparacaine with subsequent cross-sensitization to tetracaine from ophthalmic preparations. Am J Contact Dermat, 2001; 12(3):177–179.
84.
WarshawEM, SchramSE, BelsitoDV, et al.Patch-test reactions to topical anesthetics: retrospective analysis of cross-sectional data, 2001 to 2004. Dermatitis, 2008; 19(2):81–85.
85.
LiesegangTJ, PerniciaroC. Fingertip dermatitis in an ophthalmologist caused by proparacaine. Am J Ophthalmol, 1999; 127(2):240–241.
86.
RiddellCE, ReedJ, ShawS, et al.Allergic contact fingertip dermatitis secondary to proxymetacaine in an ophthalmologist. Eye (Lond), 2000; 14(Pt 6):907–908.
87.
LyonCC, BeckMH. Allergic contact dermatitis reactions to corticosteroids in periorbital inflammation and conjunctivitis. Eye (Lond), 1998; 12(Pt 1):148–149.
88.
BaeckM, De PotterP, GoossensA. Allergic contact dermatitis following ocular use of corticosteroids. J Ocul Pharmacol Ther, 2011; 27(1):83–92.
89.
BaeckM, GoossensA. Immediate and delayed allergic hypersensitivity to corticosteroids: practical guidelines. Contact Dermatitis, 2012; 66(1):38–45.
90.
UterW, LessmannH, GeierJ, et al.Is the irritant benzalkonium chloride a contact allergen? A contribution to the ongoing debate from a clinical perspective. Contact Dermatitis, 2008; 58(6):359–363.
WilsonLA, McNattJ, ReitschelR. Delayed hypersensitivity to thimerosal in soft contact lens wearers. Ophthalmology, 1981; 88(8):804–809.
93.
TostiA, TostiG. Thimerosal: a hidden allergen in ophthalmology. Contact Dermatitis, 1988; 18(5):268–273.
94.
BelsitoDV. Thimerosal: contact (non)allergen of the year. Am J Contact Dermat, 2002; 13(1):1–2.
95.
GeierJ, LessmannH, UterW, et al.Patch testing with phenylmercuric acetate. Contact Dermatitis, 2005; 53(2):117–118.
96.
SeitzCS, BröckerE-B, TrautmannA. Eyelid dermatitis due to sodium metabisulfite. Contact Dermatitis, 2006; 55(4):249–250.
97.
SchnuchA, GeierJ, UterW, et al.The biocide polyhexamethylene biguanide remains an uncommon contact allergen. Contact Dermatitis, 2007; 56(4):235–239.
98.
AertsO, SmeetsJ, AdriaenssensK, et al.Contact allergy to biguanides might explain cases of unresolved eyelid dermatitis. J Eur Acad Dermatol Venereol, 2015; 29(10):2064–2065.
99.
LeysenJ, GoossensA, LambertJ, et al.Polyhexamethylene biguanide is a relevant sensitizer in wet wipes. Contact Dermatitis, 2014; 70(5):323–325.
100.
CreytensK, GoossensA, FaberM, et al.Contact urticaria syndrome caused by polyaminopropyl biguanide in wipes for intimate hygiene. Contact Dermatitis, 2014; 71(5):307–309.
101.
García-MedinaJJ, García-MedinaM, Zanon-MorenoVC, et al.Conjunctival provocation test for the diagnosis of ocular hypersensitivity to chlorobutanol. Cornea, 2007; 26(1):94–97.
WellingJD, MaugerTF, SchoenfieldLR, et al.Chronic eyelid dermatitis secondary to cocamidopropyl betaine allergy in a patient using baby shampoo eyelid scrubs. JAMA Ophthalmol, 2014; 132(3):357–359.
104.
ThomasP, RueffF, PrzybillaB. Severe allergic contact blepharoconjunctivitis from phenylephrine in eyedrops, with corresponding T-cell hyper-responsiveness in vitro. Contact Dermatitis, 1998; 38(1):41–43.
AkitaH, AkamatsuH, MatsunagaK. Allergic contact dermatitis due to phenylephrine hydrochloride, with an unusual patch test reaction. Contact Dermatitis, 2003; 49(5):232–235.
107.
WilkinsonSM. False-negative patch test with levobunolol. Contact Dermatitis, 2001; 44(4):264.
108.
KochP. Allergic contact dermatitis due to timolol and levobunolol in eyedrops, with no cross-sensitivity to other ophthalmic beta-blockers. Contact Dermatitis, 1995; 33(2):140–141.
BasketterD, MennéT. Lymphocyte transformation test in patients with allergic contact dermatitis. Contact Dermatitis, 2005; 53(1):1.
111.
CederbrantK, HultmanP, MarcussonJA, et al.In vitro lymphocyte proliferation as compared to patch test using gold, palladium and nickel. Int Arch Allergy Immunol, 1997; 112(3):212–217.
